Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Study Summary

The study is an observational retrospective cohort study using longitudinal secondary data. Pregnant women with MS are assessed for exposure to Kesimpta and other MS disease modifying drugs (MSDMD) and followed up for adverse pregnancy and infant outcomes.

Conditions

Multiple Sclerosis

Interventions / Drugs

Multiple sclerosis disease modifying drug

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1500 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.151246+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.